NCT05496231 2025-02-03A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of AgeGlaxoSmithKlinePhase 1/2 Completed1,080 enrolled 28 charts